Annals of Oncology Advance Access originally published online on February 16, 2005
Annals of Oncology 2005 16(4):673; doi:10.1093/annonc/mdi101
© 2005 European Society for Medical Oncology
Letters |
Reply to the article "Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity" by V. R. Rozados et al. (Ann Oncol 2004; 15: 15431550): ... and in humans?
Department of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
* Email: tommaso.de-pas@ieo.it
| The first 10% of the full text of this article appears below. |
We congratulate Rozados et al. [1
] on conducting this important clinical trial, which investigates the antitumour effect of a metronomic administration of low-dose cyclophosphamide (CTX) in sarcoma rat tumour models.
The use of metronomic drug delivery is increasing in solid